Showing 2644 results
- Media Release /
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of… - Biography /
- Media Library /
- Statement /
Pagination
- ‹ Previous page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- …
- 265
- › Next page